Nicholas J. Short, MD

home / authors / nicholas-j-short-md

Articles

Nicholas J. Short, MD, on the Future of ALL and Possibilities for Transplant in These Patients

January 6th 2021

Short expanded on the future of acute lymphoblastic leukemia and transplantation necessity at the 2020 ASH Annual Meeting & Exposition.

Nicholas Short, MD, on the Surprising Significance of CR Outcomes for Patients With ALL After Frontline Therapy

Nicholas J. Short, MD

January 2nd 2021

Short described the importance of the time point of CR outcomes for patients treated as part of an ALL study presented at the 2020 American Society of Hematology Annual Meeting & Exposition.

Nicholas Short, MD Discusses MRD-Detection Assays and Blinatumomab for Patients With ALL

Nicholas J. Short, MD

December 28th 2020

Short discussed currently available assays for MRD detection, blinatumomab treatment, and other implications from an ALL study presented at the 2020 ASH Annual Meeting.

Nicholas Short, MD, on Findings from Study Examining NGS-Based MRD Assessment for Patients with ALL

Nicholas J. Short, MD

December 21st 2020

Short summarized the NGS-based MRD findings from his ALL study presented at the 2020 ASH Annual Meeting.

Highlighting PCR Monitoring of BCR-ABL1 to Identify Patients at High Risk of Relapse

Nicholas J. Short, MD

December 2nd 2016

As part of OncoTherapy Network’s coverage of the 58th Annual Meeting & Exposition of the American Society of Hematology (ASH), held December 3–6 in San Diego, California, we spoke with oncologist Nicholas J. Short, MD, of the Division of Cancer Medicine at University of Texas MD Anderson Cancer Center, in Houston.